You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAcetic acid
Accession NumberDB03166  (EXPT00423, DB04184)
TypeSmall Molecule
GroupsApproved
DescriptionAcetic acid is a product of the oxidation of ethanol and of the destructive distillation of wood. It is used locally, occasionally internally, as a counterirritant and also as a reagent. (Stedman, 26th ed) Acetic acid otic (for the ear) is an antibiotic that treats infections caused by bacteria or fungus.
Structure
Thumb
Synonyms
ACETATE ion
Acetic acid, glacial
Acetic acid, ion(1-)
Azetat
CH3-COO(-)
Ethanoat
Ethanoate
Glacial acetic acid
MeCO2 anion
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acetic AcidSolution20.65 mg/mLAuricular (otic)Dispensing Solutions, Inc.2010-01-22Not applicableUs
Acetic AcidSolution20.65 mg/mLAuricular (otic)Rebel Distributors2010-01-22Not applicableUs
Acetic AcidSolution20.65 mg/mLAuricular (otic)A S Medication Solutions2010-01-22Not applicableUs
Acetic AcidIrrigant.25 g/100mLIrrigationB. Braun Medical Inc.1979-08-06Not applicableUs
Acetic AcidSolution20.65 mg/mLAuricular (otic)Hi Tech Pharmacal Co., Inc.2010-01-22Not applicableUs
Acetic AcidSolution20.65 mg/mLAuricular (otic)Lake Erie Medical Dba Quality Care Produts Llc2010-01-22Not applicableUs
Acetic AcidIrrigant250 mg/100mLIrrigationBaxter Laboratories1982-02-19Not applicableUs
Acetic AcidSolution20.65 mg/mLAuricular (otic)A S Medication Solutions2010-01-22Not applicableUs
Acetic AcidIrrigant250 mg/100mLIrrigationHospira, Inc.1980-01-01Not applicableUs
VosolSolution20.65 mg/mLAuricular (otic)ECR Pharmaceuticals Co., Inc.2010-03-15Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Acetic AcidSolution25 mg/mLAuricular (otic)Morton Grove Pharmaceuticals, Inc.1996-07-26Not applicableUs
Acetic AcidSolution.02 mg/mLAuricular (otic)A S Medication Solutions2005-02-242017-05-31Us
Acetic AcidSolution25 mg/mLAuricular (otic)Unit Dose Services1996-07-26Not applicableUs
Acetic AcidSolution.02 mg/mLAuricular (otic)Qualitest2005-02-242017-05-31Us
BorofairSolution / drops2 mg/mLAuricular (otic)Major1994-02-25Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AcetasolNot Available
VolsolNot Available
Brand mixtures
NameLabellerIngredients
Acetasol HCActavis Mid Atlantic LLC,
Acid Concentrate D12028Althin Biopharm Inc.
Acid Concentrate D12054Althin Biopharm Inc.
Acid Concentrate D12092Althin Biopharm Inc.
Acid Concentrate D12093Baxter Laboratories
Acid Concentrate D12095Baxter Laboratories
Acid Concentrate D12119Althin Biopharm Inc.
Acid Concentrate D12132Althin Biopharm Inc.
Acid Concentrate D12150Althin Biopharm Inc.
Acid Concentrate D12247Althin Biopharm Inc.
Acid Concentrate D12250Althin Biopharm Inc.
Acid Concentrate D12261Althin Biopharm Inc.
Acid Concentrate D12268Althin Biopharm Inc.
Acid Concentrate (r04968)Genpharm Ulc
Acid Concentrate (r04969)Genpharm Ulc
Acid Concentrate (r04974)Genpharm Ulc
Acid Concentrate (r04975)Genpharm Ulc
Acid Concentrate (r04976)Genpharm Ulc
Acid Concentrate 2109Althin Biopharm Inc.
Acid Concentrate 2186Baxter Laboratories
Acid Concentrate 2187Althin Biopharm Inc.
Acid Concentrate 2189Baxter Laboratories
Acid Concentrate 2196Althin Biopharm Inc.
Acid Concentrate 2198Baxter Laboratories
Acid Concentrate Bp Rz267cGenpharm Ulc
Acid Concentrate D-18006Baxter Laboratories
Acid Concentrate D12091Althin Biopharm Inc.
Acid Concentrate D12249Althin Biopharm Inc.
Acid Concentrate D12251Althin Biopharm Inc.
Acid Concentrate D12252Althin Biopharm Inc.
Acid Concentrate D12263Althin Biopharm Inc.
Acid Concentrate D12292Baxter Laboratories
Acid Concentrate D12315Althin Biopharm Inc.
Acid Concentrate D18000Althin Biopharm Inc.
Acid Concentrate D18001Althin Biopharm Inc.
Acid Concentrate D18008Althin Biopharm Inc.
Acid Concentrate D18009Althin Biopharm Inc.
Acid Concentrate Ro4947Genpharm Ulc
Acid Concentrate Rx252cBdh Inc.
Acid Concentrate Rx253cBdh Inc.
Acid Concentrate Rz110cGenpharm Ulc
Acid Concentrate Rz144cGenpharm Ulc
Acid Concentrate Rz150cGenpharm Ulc
Acid Concentrate Rz211cGenpharm Ulc
Acid Concentrate Rz212cGenpharm Ulc
Acid Concentrate-r04948 LiqBdh Inc.
Acid Concentrate(36.83x) R04900Bdh Inc.
Acid Concentrate(36.83x) R04906Bdh Inc.
Acid Conentrate (r04930)Genpharm Ulc
Bicarb Hemodial Conc 36.83Bicarbolyte Corporation
Bicarbolyte Bicar Hemodialsis ConcBicarbolyte Corporation
Bicarbolyte Bicar Hemodialysis ConcBicarbolyte Corporation
Concentrated Haemodialysis Solution Bp-rz266cGenpharm Ulc
Fem PHPharmics, Inc.
H.E.L.P. Acetate Buffer Ph 4.85B. Braun Avitum Ag
Haemosol H-250Haemotec Inc.
Haemosol H-251Haemotec Inc.
Haemosol H-252Haemotec Inc.
Hydrocortisone and Acetic AcidQualitest
K2 Liq R04902Bdh Inc.
Naturalyte H-251Fresenius Medical Care Korea
Naturalyte H-252Fresenius Medical Care Korea
R04903 LiqBdh Inc.
R04909 LiqBdh Inc.
R04919 LiqBdh Inc.
R04922 LiqBdh Inc.
R04936 LiqBdh Inc.
R04945 LiqBdh Inc.
R04946 LiqBdh Inc.
R04972 LiqBdh Inc.
R04973 LiqBdh Inc.
Sb 1000Renal Systems, Division Of Minntech Corp.
Sb 1006Renal Systems, Division Of Minntech Corp.
Sb-110Renal Systems, Division Of Minntech Corp.
Sb-131Renal Systems, Division Of Minntech Corp.
Sb-132Renal Systems, Division Of Minntech Corp.
Star-otic SolutionStellar Pharmacal Corp
V-natalVirtus Pharmaceuticals
Virt-bal DHA PlusVirtus Pharmaceuticals
Vosol HCECR Pharmaceuticals Co., Inc.
Salts
Name/CASStructureProperties
Acetyl chloride
75-36-5
Thumb
  • InChI Key: WETWJCDKMRHUPV-UHFFFAOYSA-N
  • Monoisotopic Mass: 77.9872424
  • Average Mass: 78.5
DBSALT002299
Categories
UNIIQ40Q9N063P
CAS number64-19-7
WeightAverage: 59.044
Monoisotopic: 59.01330434
Chemical FormulaC2H3O2
InChI KeyQTBSBXVTEAMEQO-UHFFFAOYSA-M
InChI
InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)/p-1
IUPAC Name
acetate
SMILES
CC([O-])=O
Pharmacology
IndicationUsed to treat infections in the ear canal.
Structured Indications
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Bacteria
Pathways
PathwayCategorySMPDB ID
Pyruvate MetabolismMetabolicSMP00060
Canavan DiseaseDiseaseSMP00175
Pyruvate kinase deficiencyDiseaseSMP00559
Leigh SyndromeDiseaseSMP00196
Sialuria or French Type SialuriaDiseaseSMP00216
G(M2)-Gangliosidosis: Variant B, Tay-sachs diseaseDiseaseSMP00534
Sialuria or French Type SialuriaDiseaseSMP00217
Heroin Action PathwayDrug actionSMP00407
Primary hyperoxaluria II, PH2DiseaseSMP00558
Heroin Metabolism PathwayDrug metabolismSMP00623
Amino Sugar MetabolismMetabolicSMP00045
Aspartate MetabolismMetabolicSMP00067
Pyruvate Decarboxylase E1 Component Deficiency (PDHE1 Deficiency)DiseaseSMP00334
Tay-Sachs DiseaseDiseaseSMP00390
HypoacetylaspartiaDiseaseSMP00192
Pyruvate Dehydrogenase Complex DeficiencyDiseaseSMP00212
Salla Disease/Infantile Sialic Acid Storage DiseaseDiseaseSMP00240
Disulfiram Action PathwayDrug actionSMP00429
Ethanol DegradationMetabolicSMP00449
Fatty Acid BiosynthesisMetabolicSMP00456
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug InteractionsNot Available
Food InteractionsNot Available
References
Synthesis Reference

Earl M. Chamberlin, Warren K. Russ, Jr., George G. Hazen, “Process for preparing [1-oxo-2-cyclopentyl (or 2-isopropyl)-2-methyl-6,7-dichloro-5-indanyloxy] acetic acid.” U.S. Patent US3950408, issued April, 1928.

US3950408
General References
  1. eMedicine [Link]
External Links
ATC CodesS02AA10G01AD02
AHFS CodesNot Available
PDB Entries
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials
PhaseStatusPurposeConditionsCount
Not AvailableActive Not RecruitingPreventionCervical Cancers1
Not AvailableNot Yet RecruitingDiagnosticColon Nos Polypectomy Tubular Adenoma / Colorectal Cancers / Serrated Adenomas1
Not AvailableNot Yet RecruitingDiagnosticEsophagus, Barrett1
Not AvailableRecruitingBasic ScienceCerebral Blood Flow / Gut Microbiome / Metabolism1
Not AvailableRecruitingDiagnosticCervical Cancers1
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
IrrigantIrrigation.25 g/100mL
IrrigantIrrigation250 mg/100mL
SolutionAuricular (otic).02 mg/mL
SolutionAuricular (otic)25 mg/mL
LiquidHemodialysis
SolutionHemodialysis
Solution / dropsAuricular (otic)2 mg/mL
JellyVaginal
Tablet, coatedOral
Kit
SolutionAuricular (otic)20.65 mg/mL
SolutionAuricular (otic)
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point16.6 °CPhysProp
boiling point117.9 °CPhysProp
water solubility1E+006 mg/L (at 25 °C)MERCK INDEX (1996)
logP-0.17HANSCH,C ET AL. (1995)
logS1.22ADME Research, USCD
pKa4.76 (at 25 °C)SERJEANT,EP & DEMPSEY,B (1979)
Predicted Properties
PropertyValueSource
Water Solubility490.0 mg/mLALOGPS
logP-0.29ALOGPS
logP-0.22ChemAxon
logS0.8ALOGPS
pKa (Strongest Acidic)4.54ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area40.13 Å2ChemAxon
Rotatable Bond Count0ChemAxon
Refractivity23.48 m3·mol-1ChemAxon
Polarizability4.96 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9502
Blood Brain Barrier+0.9742
Caco-2 permeable+0.5968
P-glycoprotein substrateNon-substrate0.8714
P-glycoprotein inhibitor INon-inhibitor0.99
P-glycoprotein inhibitor IINon-inhibitor0.992
Renal organic cation transporterNon-inhibitor0.9466
CYP450 2C9 substrateNon-substrate0.7913
CYP450 2D6 substrateNon-substrate0.9384
CYP450 3A4 substrateNon-substrate0.7921
CYP450 1A2 substrateNon-inhibitor0.8774
CYP450 2C9 inhibitorNon-inhibitor0.9482
CYP450 2D6 inhibitorNon-inhibitor0.9667
CYP450 2C19 inhibitorNon-inhibitor0.9786
CYP450 3A4 inhibitorNon-inhibitor0.9854
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9818
Ames testNon AMES toxic0.9635
CarcinogenicityCarcinogens 0.6222
BiodegradationReady biodegradable0.9758
Rat acute toxicity1.6315 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9666
hERG inhibition (predictor II)Non-inhibitor0.9889
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as carboxylic acids. These are compounds containing a carboxylic acid group with the formula -C(=O)OH.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassCarboxylic acids
Direct ParentCarboxylic acids
Alternative Parents
Substituents
  • Monocarboxylic acid or derivatives
  • Carboxylic acid
  • Organic oxygen compound
  • Organic oxide
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Organic anion
  • Aliphatic acyclic compound
Molecular FrameworkAliphatic acyclic compounds
External Descriptors

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name:
SLCO2B1
Uniprot ID:
O94956
Molecular Weight:
76709.98 Da
References
  1. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther. 2003 Aug;306(2):703-8. Epub 2003 Apr 30. [PubMed:12724351 ]
  2. Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization of pH-sensitive organic anion transporting polypeptide OATP-B in human. J Pharmacol Exp Ther. 2004 Feb;308(2):438-45. Epub 2003 Nov 10. [PubMed:14610227 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Symporter activity
Specific Function:
Proton-coupled monocarboxylate transporter. Catalyzes the rapid transport across the plasma membrane of many monocarboxylates such as lactate, pyruvate, branched-chain oxo acids derived from leucine, valine and isoleucine, and the ketone bodies acetoacetate, beta-hydroxybutyrate and acetate. Depending on the tissue and on cicumstances, mediates the import or export of lactic acid and ketone bod...
Gene Name:
SLC16A1
Uniprot ID:
P53985
Molecular Weight:
53943.685 Da
References
  1. Tamai I, Sai Y, Ono A, Kido Y, Yabuuchi H, Takanaga H, Satoh E, Ogihara T, Amano O, Izeki S, Tsuji A: Immunohistochemical and functional characterization of pH-dependent intestinal absorption of weak organic acids by the monocarboxylic acid transporter MCT1. J Pharm Pharmacol. 1999 Oct;51(10):1113-21. [PubMed:10579682 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on February 24, 2017 10:32